LINCOLN PHARMACEUTICALS LTD. - 531633 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
We hereby submit the confirmation certificate as received from M/S Link Intime India Private Limited, Registrar and Share Transfer Agent for the Quarter Ended June 30, 2024. LINCOLN PHARMACEUTICALS LTD. - 531633 - Closure of Trading Window
Intimation of Closure of Trading Window for the Quarter ended June 30, 2024. LINCOLN PHARMACEUTICALS LTD. - 531633 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Munjal Mahendrabhai Patel & PACs LINCOLN PHARMACEUTICALS LTD. - 531633 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Munjal Mahendrabhai Patel & PACs LINCOLN PHARMACEUTICALS LTD. - 531633 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Annual Secretarial Compliance Report for the Financial Year Ended March 31, 2024. LINCOLN PHARMACEUTICALS LTD. - 531633 - Shareholder Meeting / Postal Ballot-Scrutinizer"s Report
Outcome of Postal Ballot- Voting Results and Scrutinizer Report LINCOLN PHARMACEUTICALS LTD. - 531633 - Shareholder Meeting / Postal Ballot-Outcome of Postal Ballot
Outcome of Postal Ballot-Voting Results and Scrutinizer Report LINCOLN PHARMACEUTICALS LTD. - 531633 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 , we attach herewith transcript of Conference Call held on May 16, 2024 . A copy of the same is available on the website of the Company. LINCOLN PHARMACEUTICALS LTD. - 531633 - Announcement under Regulation 30 (LODR)-Newspaper Publication
We enclosed herewith the copies of published newspaper advertisement with respect to Audited (Standalone & Consolidated) Financial Results of the Company for the Quarter and Year ended March 31, 2024. LINCOLN PHARMACEUTICALS LTD. - 531633 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
We wish to inform you that the Company participated in investor conference- Call Conference on May 16, 2024. No Unpublished Price Sensitive Information (UPSI) was shared / discussed in the meeting with investors.